Published September 4, 2025
| Version v1
Other
Open
Act as an expert in hospital pharmacy. Show me if there are significant differences or what the differences are in the safety profiles between anagrelide and peginterferon alfa-2A for a diagnosis of chronic myelodysplastic syndrome (TE/PV) JAK 2 positive in 31-50% of the alleles.
Description
Both anagrelide and peginterferon alfa-2A are used in managing conditions like ET, but their safety profiles differ significantly. Anagrelide may present more cardiovascular risks, while peginterferon often leads to systemic side effects like fatigue and flu-like symptoms.